Investing.com UK - Financial Markets Worldwide
🚀 ProPicks AI Hits +34.9% Return!Read Now

Altimmune Shares Fall Despite Fatty Liver Disease Study Meets Primary Goal

Published 14/09/2022, 14:25
© Reuters. Altimmune Shares Fall Despite Fatty Liver Disease Study Meets Primary Goal
ALT
-

  • Altimmune Inc (NASDAQ: ALT) shares plunged after topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD).
  • The trial assessed three dose levels, 1.2 mg, 1.8 mg, and 2.4 mg.
  • The trial met its primary endpoint in all pemvidutide treatment groups.
  • At the 1.8 mg dose (with and without diabetes), pemvidutide achieved a mean reduction of the liver fat content of 68.5%, with 94.4% of subjects achieving a 30% reduction in liver fat, 72.2% achieving a 50% reduction in liver fat, and 55.6% of subjects achieving normalization of liver fat.
  • In addition, mean liver enzyme levels declined in all subjects. In subjects with baseline serum ALT above 30 IU/L, levels declined more than 17 IU/L at all doses and 27.0 IU/L in the 2.4 mg dose cohort.
  • Related: See Why Altimmune Stock Plunged After Obesity Trial Data.
  • The trial also met its key secondary endpoint in all pemvidutide treatment groups, with mean weight losses of 4.9% (placebo-adjusted 4.7%) in subjects without diabetes and 4.4% in subjects with diabetes (placebo-adjusted 3.9%) achieved at the 1.8 and 2.4 mg doses, respectively.
  • Pemvidutide was reported to be generally well tolerated. Gastrointestinal events comprised most adverse events (AEs), predominantly mild and transient.
  • Two subjects treated with pemvidutide discontinued treatment due to AEs, both secondary to gastrointestinal intolerability.
  • Price Action: ALT shares are down 44.2% at $11.36 during the premarket session on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.